PSMA PET在分化型甲状腺癌中的临床应用进展  

Clinical application progress of PSMA PET in differentiated thyroid cancer

作　　者：张恩碧 张万春 Zhang Enbi;Zhang Wanchun(Department of Medical Imaging,Shanxi Medical University,Taiyuan 030001,China;Department of Nuclear Medicine,Shanxi Bethune Hospital,Taiyuan 030032,China)

机构地区：[1]山西医科大学医学影像学院,太原030001 [2]山西白求恩医院核医学科,太原030032

出　　处：《中华核医学与分子影像杂志》2024年第5期313-316,共4页Chinese Journal of Nuclear Medicine and Molecular Imaging

摘　　要：分化型甲状腺癌(DTC)是常见的内分泌肿瘤之一。绝大多数的DTC预后较好,部分中高危DTC患者可能在自然病程或治疗过程中出现摄碘能力下降,或虽然保持摄碘能力但仍出现病情进展。18F-FDG PET/CT对探测此类患者的复发或转移病灶有较高的提示意义,但也会有假阴性的可能。肿瘤新生血管在肿瘤转移、侵袭的过程中发挥重要作用。前列腺特异膜抗原(PSMA)在DTC新生血管中也有表达,提示PSMA PET在甲状腺癌中具有潜在价值。该文对PSMA PET在DTC中的临床应用进展进行综述。Differentiated thyroid cancer(DTC)is one of the common endocrine tumors,and the vast majority of DTC have a good prognosis.Some medium-and high-risk patients with DTC may have decreased iodine uptake or progression in spite of maintaining iodine uptake in the natural course of disease or during treatment.18F-FDG PET/CT is of high significance in detecting recurrent or metastatic lesions in such patients,but there is also a possibility of false negative result.Tumor neovascularization plays an important role in the process of tumor metastasis and invasion.Prostate specific membrane antigen(PSMA)is also expressed in DTC neovascularization,suggesting that PSMA PET has potential value in thyroid cancer.This article reviews the clinical application progress of PSMA PET in DTC.

关 键 词：甲状腺肿瘤 前列腺特异膜抗原 正电子发射断层显像术 发展趋势 

分 类 号：R736.1[医药卫生—肿瘤] R816.6[医药卫生—临床医学]